MISSISSAUGA, ON, Nov. 17 /CNW/ - YM BioSciences Inc. (AMEX:YMI, TSX:YM, AIM:YMBA), the cancer drug development company, today announced that its majority-owned subsidiary, CIMYM Inc., has partnered with Innogene Kalbiotech Ltd (IGK) of Singapore to expand the development program for its humanized, EGF receptor-targeting monoclonal antibody, nimotuzumab. IGK is the biotech subsidiary of P.T Kalbe Farma Tbk (JK.KLBF), a public company based in Jakarta, Indonesia with more than 8,100 employees and revenues exceeding US$300 million.